ReviewAntimicrobial agents and chemotherapy2015
Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.
Review in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 116 citations in OpenAlex.
- Protection AgainstPharmaceutics · 2026Article
- Unraveling the role of host kinase PIM1 in Toxoplasma gondii infection: Implications for therapies.PLoS neglected tropical diseases · 2026Article
- BKI-1748 confers a high level of protection against ovine congenital toxoplasmosis when administered after IgM seroconversion.Frontiers in cellular and infection microbiology · 2026Article
- Ubiquitin-activating enzyme1 (TgUAE1) acts as a key regulator of Toxoplasma gondii lytic cycle and homeostasis.Communications biology · 2025Article
- Study of anti-Toxoplasma gondii effect of mPEG-PCL copolymeric loaded with pyrimethamine, in vitro.AMB Express · 2025Article
- High-Throughput Repurposing Screen Reveals Compounds with Activity againstACS infectious diseases · 2025Article
- Treatment with BKI-1748 afterAntimicrobial agents and chemotherapy · 2025Article
- Antiproliferative and Morphological Analysis Triggered by Drugs Contained in the Medicines for Malaria Venture COVID-Box AgainstMicroorganisms · 2024Article
- High Throughput Repurposing Screen Reveals Compounds with Activity AgainstbioRxiv : the preprint server for biology · 2024Article
- The Effects and Mechanism of ATM Kinase Inhibitors inInternational journal of molecular sciences · 2024Article
- Imiquimod Reverses Chronic Toxoplasmosis-Associated Behavioral and Neurocognitive Anomalies in a Rat Model.Biomedicines · 2024Article
- Apigeninidin chloride disruptsFrontiers in cellular and infection microbiology · 2024Article
- Lentinan has a beneficial effect on cognitive deficits induced by chronic Toxoplasma gondii infection in mice.Parasites & vectors · 2023Article
- Advances in Protozoan Epigenetic Targets and Their Inhibitors for the Development of New Potential Drugs.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A Metabolomic and Transcriptomic Study Revealed the Mechanisms of Lumefantrine Inhibition ofInternational journal of molecular sciences · 2023Article
- TZD-Based Hybrid Molecules Act as Dual Anti-International journal of molecular sciences · 2023Article
- Therapeutic Implications of the Microbial Hypothesis of Mental Illness.Current topics in behavioral neurosciences · 2023Review
- Two small-molecule inhibitors ofFrontiers in cellular and infection microbiology · 2023Article
- New Nucleic Base-Tethered Trithiolato-Bridged Dinuclear Ruthenium(II)-Arene Compounds: Synthesis and Antiparasitic Activity.Molecules (Basel, Switzerland) · 2022Article
- In Vitro and In Vivo Activities of Tilmicosin and Acetylisovaleryltylosin Tartrate againstInternational journal of molecular sciences · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Toxoplasma gondii is an apicomplexan parasite of humans and other mammals, including livestock and companion animals. While chemotherapeutic regimens, including pyrimethamine and sulfadiazine regimens, ameliorate acute or recrudescent disease such as toxoplasmic encephalitis or ocular toxoplasmosis, these drugs are often toxic to the host. Moreover, no approved options are available to treat infected women who are pregnant. Lastly, no drug regimen has shown the ability to eradicate the chronic stage of infection, which is characterized by chemoresistant intracellular cysts that persist for the life of the host. In an effort to promote additional chemotherapeutic options, we now evaluate clinically available drugs that have shown efficacy in disease models but which lack clinical case reports. Ideally, less-toxic treatments for the acute disease can be identified and developed, with an additional goal of cyst clearance from human and animal hosts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.